I would personally temper my expectations here a little on near term profitability.
Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.
EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.
If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.
The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.
- Forums
- ASX - By Stock
- EYE
- Nova Eye Medical (EYE) Discussion
Nova Eye Medical (EYE) Discussion, page-2480
-
- There are more pages in this discussion • 708 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $54.91M |
Open | High | Low | Value | Volume |
24.0¢ | 24.5¢ | 24.0¢ | $110.1K | 458.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 432506 | 23.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 169560 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 432506 | 0.235 |
2 | 93400 | 0.230 |
3 | 75000 | 0.225 |
6 | 187721 | 0.220 |
3 | 188594 | 0.215 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 169560 | 3 |
0.250 | 3996 | 1 |
0.255 | 16768 | 2 |
0.260 | 50000 | 1 |
0.265 | 70000 | 3 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |